Associate Professor, Health Policy & Behavioral Sciences, School of Public Health, Georgia State University
November 5, 2026
As blood-based biomarker and genetic tests make it possible to detect early biological signs of Alzheimer’s disease and identify who’s most at risk, important questions arise about privacy, stigma, and potential discrimination in areas such as employment, housing, and insurance. Join public health expert Jalayne J. Arias, for a discussion of the legal and ethical implications of Alzheimer’s biomarker and genetic testing, including what individuals and families should know before getting tested.
BrightFocus Foundation is a premier global nonprofit funder of research to defeat Alzheimer’s, macular degeneration, and glaucoma. Since its inception more than 50 years ago, BrightFocus and its flagship research programs—Alzheimer’s Disease Research, Macular Degeneration Research, and National Glaucoma Research—has awarded more than $330 million in research grants to scientists around the world, catalyzing thousands of scientific breakthroughs, life-enhancing treatments, and diagnostic tools. We also share the latest research findings, expert information, and resources to empower the millions impacted by these devastating diseases. Learn more at brightfocus.org.
Disclaimer: The information provided here is a public service of BrightFocus Foundation and is not intended to constitute medical advice. Please consult your physician for personalized medical, dietary, and/or exercise advice. Any medications or supplements should only be taken under medical supervision. BrightFocus Foundation does not endorse any medical products or therapies.
Every Donation is a Step Forward in the Fight Against Alzheimer’s
Your donation powers cutting-edge research and helps scientists explore new treatments. Help bring us closer to a cure and provide valuable information to the public.
Donate Today
